Position in JANX
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$652,227
+$261,386 QoQ
Shares Held
46,923
+65.7% QoQ
Ownership
0.077%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0%
Shared 97%
None 3%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Invesco Ltd. holds $10,689,611,381 across 259 Biotechnology names. JANX ranks #161 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,331,554 | $2,380,752,123 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,180,631 | $1,684,842,735 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,783,394 | $920,941,572 | |
| 4 | INSM |
INSMED Inc
|
4,523,921 | $739,751,561 | |
| 5 | ARGX |
Argenx SE
|
594,697 | $434,277,482 | |
| 6 | INCY |
Incyte Corp
|
3,870,764 | $364,316,298 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
4,592,814 | $341,062,362 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
4,012,494 | $259,327,483 |
All Filings in JANX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $652,227 | 46,923 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $390,841 | 28,322 | Shares | Defined | 2026-02-19 | |
| 2025-09-30 | $598,020 | 24,469 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $422,705 | 18,299 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $6,968,916 | 258,108 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $15,240,800 | 284,662 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $451,481 | 9,938 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $404,363 | 9,653 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $293,932 | 7,807 | Shares | Defined | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||